Clinical trial registry record

A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 12, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03345082
Last registry update
January 12, 2021
Status
Completed
Phase
Phase 2
Sponsor
Opthea Limited
Enrollment
366
Countries
United States, Czechia, France, Hungary, Israel, Italy, Latvia, Poland, Spain, United Kingdom
Match confidence
60%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
366
Population
ALL · 50 Years
Duration
2017-11-06 to 2019-05-14
Intervention
OPT-302; ranibizumab; sham intravitreal injection
Comparator
Not reported
Outcomes measured
Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) — Baseline to Wee…; Proportion of participants gaining 15 or more ETDRS BCVA letters — Baseline to Week 24; Area under the ETDRS BCVA over time curve — Baseline to Week 24; Change in central subfield thickness (CST) on spectral domain optical coherence tomography (SD-OCT) — Baseline to Week…; Change in intra-retinal fluid and sub-retinal fluid on SD-OCT — Baseline to Week 24; Proportion of participants losing 15 or more letters (on ETDRS BCVA chart) — Baseline to Week 24
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 60% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON